Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16

Cancer Research

Volumn 56, Issue 10, 1996, Pages 2256-2262

  Mirakhur, Beloo ^a   Parekh, Hemant K ^a   Simpkins, Henry ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CHROMOSOME 11; CHROMOSOME 16; FEMALE; GENE LOCATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; CARCINOMA; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 16; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HUMANS; HYBRID CELLS; L CELLS (CELL LINE); MICE; OVARIAN NEOPLASMS; PHENOTYPE; TUMOR CELLS, CULTURED;

EID: 0029901410     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ozols, R. F., and Young, R. C Chemotherapy of ovarian cancer. Semin. Oncol , 18: 222-232, 1991
2. Loehrer, P J., and Einhorn, L H. Cisplatin. Ann Intern. Med., 100 704-713, 1984.
3. Sherman, S. E , and Lippard, S J. Structural aspects of platinum anticancer drug interactions with DNA. Chem. Rev., 87. 1153-1181, 1987.
4. Eastman, A. Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem.-Biol. Interact., 61: 241-248, 1987
5. Roberts, J. D , and Freidlos, F. Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol & Ther , 34: 215-246, 1987.
6. Pinto, A. L., and Lippard, S. J Binding of the antitumor drug cis-diaminedichloroplatinum (II) (cisplatin) to DNA Biochim. Biophys Acta, 780. 167-180, 1985.
7. 2{d(pGpG)}]. Science (Washington DC), 230: 412-417, 1985.
8. Inoue, K., Mukaiyama, T., Mitsui, I., and Ogawa, M. In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay Cancer Chemother. Pharmacol , 15: 208-213, 1985.
9. Andrews, P A., and Howell, S. B Cellular pharmacology of cisplatin Perspectives on mechanisms of acquired resistance Cancer Cells (Cold Spring Harbor), 2: 35-43, 1990.
10. Jekunen, A. P., Hom, D. K., Alcaraz, J E , Eastman, A , and Howell S B. Cellular pharmacology of dichloro(ethylenediamine)platinum (II) in cisplatin-sensitive and -resistant human ovarian carcinoma cells. Cancer Res., 54: 2680-2687, 1994.
11. Chu, G. Cellular responses to cisplatin. J. Biol. Chem., 269: 787-790, 1994.
12. Teicher, B. A., Holden, S A., Kelley, M. J., Shea, T. C , Cucchi, C. A., Rosowsky A., Henner, W. D , and Frei, E , III. Characterization of a human squamous carcinoma cell line resistant to cis-diaminedichloroplatinum (II). Cancer Res , 47: 388-393, 1987
13. Andrews, P. A., Velury, S., Mann, S. C., and Howell, S. B. cis-diaminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res., 48: 68-73, 1988.
14. Waud, W. R. Differential uptake of cis-diaminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res., 47: 6549-6555, 1987.
15. Hamilton, T C., Winker, M. A , Louei, K. G., Batist, G., Behrens, B C., Tsuruo, T., Grotzinger, K. R., McKoy, W. M , Young, R. C., and Ozols, R. F. Augmentation of Adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine and sulfoximine mediated glutathione depletion. Biochem. Pharmacol , 34. 2583-2586, 1985.
16. Richon, V M , Schulte, N., and Eastman, A. Multiple mechanisms of resistance to cis-diaminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res., 47: 2056-2061, 1987
17. Wolf, C. R., Hayward, I P , Lawrie, S. S , Buckton, K., Mcintyre, M. A., Adams, J., Lewis, A. D., Scott, A R R., and Smyth, J. F Cellular hetrogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient Int. J. Cancer , 39: 696-701, 1987.
18. Sabet, M. K , Lu, Y., Leong, L , Haedick, K., and Scalon, K J Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. Eur. J Cancer , 26. 383-390, 1990.
19. Zwelling, L. A , Michaeles, S , Schwrtz, H , Dobson, P P , and Kohn, K. W. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diaminedichloroplatinum (II) and L-phenylalanine mustard. Cancer Res., 41: 2791-2794, 1981.
20. Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M P., Hamer, D H., and Lazo, J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science (Washington DC), 241: 1813-1815, 1988.
21. Kasahara, K , Fujiwara, Y., Nishio, K., Ohmori, T., Sugimoto, Y., Komiya, K , Matsuda, T., and Saijo, N Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin Cancer Res., 51: 3237-3242, 1991.
22. Schilder, R J., Hall, L., Monks, A., Handel, L. M , Fornace, A. J., Jr., Ozols R. F , Fojo, A. T , and Hamilton, T. C. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer Int. J. Cancer., 45: 416-422, 1990.
23. Andrews, P. A., Murphy, M P., and Howell, S. B. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 19: 149-154, 1987.
24. Plooy, A. C M., van Dijk, M , Berends, F., and Lohman, P. H. M Formation and repair of interstrand cross-links in relation to cytotoxity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diaminedichloroplatinum (II) Cancer Res , 45: 4178-4184, 1985.
25. Masuda, H., Ozols, R. F , Lai, G. M., Fojo, A , Rothenberg, H., and Hamilton, T. C Increased DNA repair as a mechanism of acquired resistance to cis-diaminedichloroplatinum (II) in human ovarian cancer cell lines Cancer Res., 48. 5713-5716, 1988.
26. Andrews, P A., Murphy, M P., and Howell S B. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion Cancer Res , 45 6250-6253, 1985
27. Mamenta, E. L., Poma, E. E., Kaufmann, W K., Delmastro, D. A., Grady, H. L., and Chaney, S. G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin resistant human ovarian carcinoma cell lines. Cancer Res., 54: 3500-3505, 1994.
28. Parekh, H., and Simpkins, H. The differential expression of cytokeratin 18 in cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its association with drug sensitivity. Cancer Res., 55: 5203-5206, 1995.
29. Christen, R. D., Jekunen, A. P., Jones, J. A., Thiebaut, F., Shalinsky, D. R., and Howell, S. B. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacological alteration of microtubules. J. Clin. Invest., 92: 431-440, 1993
30. Andrews, P. A., and Albright, K. D. Mitochondrial defects in cis-diaminedichloroplatinum (II)-resistant human ovarian carcinoma cells. Cancer Res., 52: 1895-1901, 1992.
31. Isonishi, S , Andrews, P. A., and Howell, S. B Increased sensitivity to cis-diaminedichloroplatinum (II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbal-13-acetate. J. Biol. Chem , 265: 3623-3627, 1990.
32. Isonishi, S., Jekunen, A. P., Hom, D. H., Eastman, A., Edelsetein, P. S., Thiebaut, F. B., Christen, R. D., and Howell, S. B. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-α. J. Clin. Invest., 90: 1436-1442, 1992.
33. Mann, S. C., Andrews, P A., and Howell, S. B. Modulation of cis-diaminedichloroplatinum (II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int. J Cancer., 48: 866-872, 1991
34. Littlefield, J. W. The use of drug-resistant markers to study the hybridization of mouse fibroblasts. Exp. Cell Res., 41: 190-196, 1966.
35. Lugo, T. G., and Baker, R M. Chromosome-mediated gene transfer of HPRT and APRT in an intraspecific human cell system. Somatic Cell Genet , 9: 175-188, 1983.
36. D'Eustachio, P., and Ruddle, F. H. Somatic cell genetics and gene families Science (Washington DC), 220: 919-924, 1983.
37. Saxon, P J , Srivatsan E. S., Leipzig, V. G., Sameshima, J. H., and Stanbridge, E. J. Selective transfer of individual chromosomes to recipient cells. Mol. Cell. Biol., 5. 140-146, 1985.
38. Abbott, C., and Povey, S. Development of human chromosome-specific PCR primers for characterization of somatic cell hybrids. Genomics, 9. 73-77, 1991
39. Theune, S., Fung, J., Todd, S., Sakaguchi, A. Y., and Naylor, S. L. PCR primers for human chromosomes for the rapid analysis of somatic cell hybrids. Genomics, 9: 511-516, 1991.
40. Triputti, P., Bacciocchi, G., Accolla, R. S , Mantero, G , De Bellis, G , Manoni, M., Cassani, G., and Corneo, G. Detection of human chromosomes in somatic cell hybrids by PCR analysis. Cytogenet Cell Genet , 62: 1-4, 1993.
41. Parekh, H., and Simpkins, H. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells. Cancer Chemother. Pharmacol., 37: 457-462, 1996
42. Svinarich, D M., and Krawetz, S. A. Gene assignment by quantitative hybridization analysis of somatic cell hybrids. Biotechniques, 14: 82-86, 1993.
43. Lugo, T. G., Handelin, B., Killary, A. M., Housman, D. E., and Fournier, R. E. K. Isolation of microcell hybrid clones containing retroviral vector insertions into specific human chromosomes. Mol. Cell. Biol., 7. 2814-2820, 1987.
44. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H , Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J , Kurz, E. U., Duncan, A M. V., and Deeley, R G Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
45. Parekh, H., and Simpkins, H. Species-specific differences in taxol transport and its cytotoxicity against human and rodent cells. Biochem. Pharmacol., 51: 301-311, 1996.
46. Slovak, M. L , Ho, J P., Bhardwaj, G , Kurz, E. U , Deeley, R. G., and Cole, S. P C. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res., 53: 3221-3225, 1993.
47. Rome, L., Kedersha, N., and Chugani, D. Unlocking vaults: organelles in search of a function Trends Cell Biol , 1: 47-50, 1991.
48. Izquierdo, M. A , van der Zee, A. G. J., Vermorken, J. B., van der Valk, P., Belien, J A. M., Giaccone, G , Scheffer, G. L , Flens, M. J , Pinedo, H. M., Kenemans, P., Meijer, C. J. L. M., de Vries, E. G. E., and Scheper, R. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian cancer J. Natl. Cancer Inst., 87: 1230-1237, 1995.
49. Tanaka, K., and Wood, R. D. Xeroderma pigmentosum and nucleotide excision repair of DNA. Trends Biochem Sci , 19: 83-86, 1994.
50. Endresen, L., Schjerven, L., and Rugstad, H. E. Tumors from a cell strain with a high content of metallothionein show enhanced resistance to cis-dichlorodiamine-platinum. Acta Pharmacol. Toxicol., 55: 183-187, 1984
51. Imura, N., Naganuma, A , and Satoh, M. Metallothionein as a resistance factor for antitumor drugs Jpn J. Cancer Chemother., 16: 599-604, 1989.
52. Zelazowski, A. J., Garvey, J S., and Hoeschele, J. D. In vivo and in vitro binding of platinum to metallothionein Arch Biochem. Biophys., 229: 246-252, 1984.
53. Bruhn, S., Pil, P., Essigmann, J. M , Housman, D E., and Lippard, S. J. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin Proc. Natl. Acad. Sci USA, 89: 2307-2311, 1992.
54. Hughes, E N , Engelsberg, B. N., and Billings, P C. Purification of nuclear proteins that bind to cisplatin-damaged DNA. J. Biol. Chem., 267. 13520-13527, 1992.